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Abstract
Background. The cell and gene therapy (CGT) field is at a critical juncture. Clinical successes have underpinned the re-
quirement for developing manufacturing capacity suited to patient-specific therapies that can satisfy the eventual demand
post-launch. Decentralised or ‘redistributed’ manufacturing divides manufacturing capacity across geographic regions, prom-
ising local, responsive manufacturing, customised to the end user, and is an attractive solution to overcome challenges facing
the CGT manufacturing chain. Methods. A study was undertaken building on previous, so far unpublished, semi-
structured interviews with key opinion leaders in advanced therapy research, manufacturing and clinical practice.The qualitative
findings were applied to construct a cost of goods model that permitted the cost impact of regional siting to be combined
with variable and fixed costs of manufacture of a mesenchymal stromal cell product. Results. Using the United Kingdom
as an exemplar, cost disparities between regions were examined. Per patient dose costs of ~£1,800 per 75,000,000 cells
were observed. Financial savings from situating the facility outside of London allow 25–41 additional staff or 24–35 extra
manufacturing vessels to be employed. Decentralised quality control to mitigate site-to-site variation was examined. Partial
decentralisation of quality control was observed to be financially possible and an attractive option for facilitating release ‘at
risk’. Discussion. There are important challenges that obstruct the easy adoption of decentralised manufacturing that have
the potential to undermine the market success of otherwise promising products. By using the United Kingdom as an ex-
emplar, the modelled data provide a framework to inform similar regional policy considerations across other global territories.
KeyWords: advanced manufacturing technology, cell and gene therapy, cost of goods, decentralised manufacturing, organisational
change, quality control
Introduction
Disruptive changes in advanced therapy manufacturing
Centralised manufacturing has been the dominant
model for large-scale production of goods since the
Industrial Revolution [1]. Centralising workers and ma-
terials to benefit from economies of scale was pioneered
by the early ‘Fordist’ factories and allowed costs to
be contained [2]. Increasing attention is now being
paid to the potential for a network of decentralised
production facilities to provide cell and gene therapy
(CGT) manufacturing capacity [3]. In common with
other regions of the developed world, the United
Kingdom is under pressure to increase the efficiency
of manufacturing, to create valuable professional-
level jobs across all regions [4] and to reduce carbon
footprint associated with the shipping of thermally con-
trolled goods over long distances [5].
Decentralised manufacturing (DCM) divides
manufacturing capacity across geographic regions and
thus represents a radical departure for most existing
healthcare supply systems. To achieve this, signifi-
cant changes must be made to the traditional flow of
materials and information and the aggregation of
manufacturing processes [2]. Both centralised and
DCM paradigms can be conceptualised as ‘process
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modules’ and the options for each can then be ex-
amined separately (Figure 1).
Despite the challenges in terms of batch repro-
ducibility that decentralisation of manufacturing
facilities may introduce [1], it remains an attractive
choice in principle for manufacturing certain CGTs.
This is primarily due to the perishability of these prod-
ucts and the limited options for storage and shipping
making long-distance transit undesirable [6]. Addi-
tionally, products that require a late-stage customisation
or ‘mass customisation’, such as a bio-printed three-
dimensional (3D) scaffold, are particularly suited to
being manufactured close to a clinical setting [7].
A decentralised network allows manufacturing to
be located proximal to treatment centres and this dic-
tates to some degree the geographical location. The
social function of the DCM suite and associated treat-
ment centres demands that they should be situated in
the heart of the society that they serve. Similarly, ac-
cessibility is paramount and the centres must be within
reach of their users. Using an out-of-town brownfield
site or suburban estate, it may be cheaper to establish
a traditional manufacturing centre, but these do not
necessarily suit delivery of products to users. Defin-
ing the catchment areas for treatment is a first step in
deciding the location [8], however, there are a mul-
titude of other regional pressures and business
operational concerns that affect the implementation
of a successful DCM network.
The decentralised manufacturing ‘Smart Factory’
Production of CGTs has different requirements from
pharmaceuticals or biologics. Attempts to use exist-
ing manufacturing strategies have yielded poor
outcomes [9,10].With the rapid advancements in the
technical capability for CGT manufacturing systems,
the promise of large-scale, small-footprint manufac-
turing is becoming a reality through, for example,
autonomous biological factories.The purpose of such
a factory is to operate to a pre-defined set of process
instructions via installed firmware programs to reduce
operator discretion. It is this reduction of operator dis-
cretion that would reduce variability across a DCM
network and is thus a critical requirement for success.
The interconnection of industrial environments has
been an area of intense systems engineering re-
search. The exact terminology varies between
stakeholders and includes “Smart Factories” (IBM),
“Industrial Internet” (GE), “The Factory of the
Future” (Airbus) and “Industrie 4.0” (Germany)
[11,12].The key themes include next-generation manu-
facturing, use of big data, automation, logistics and
supply chain management, smart networks and com-
munication.Together these describe an interconnected
manufacturing value chain with equipment configu-
rations able to respond autonomously to demands and
pressures with minimal operator interaction.
Although there are promising candidate ‘smart
factory’ solutions both commercially available and
under development [13], there is currently no truly
autonomous solution able to claim successes in all of
these defining areas of a ‘smart factory’. Of the com-
mercially available systems [13], two platforms are
available that, with further modification, could begin
to fulfil the requirements or an autonomous ‘smart
micro-factory’ suitable for DCM. These two exem-
plar platforms are described in Figure 2. Both provide
semi-autonomous culture of cell products, but differ
in their approach with one using existing culture tech-
nology (flasks) and mimicking human processes while
the modular stirred tank reactor scales the process up
to facilitate greater culture potential in a smaller foot-
print.This scale-up approach is undoubtedly more cost
effective [14] and has the additional benefit of being
simpler than flask-based approaches to enhance when
developments in sensory and manipulation technol-
ogy justify retrofitting such technology.
A UK case study of progress toward DCM
With an active and capable manufacturing work-
force, an actively engaged single-payer healthcare sector
and a strong commitment from central government
to place advanced therapy manufacturing at the fore-
front of investment policy, the United Kingdom
remains an attractive choice for a hypothetical DCM
environment.The recent vote to leave the European
Union has generated intense dialogue around the topic
of the relationship between the United Kingdom and
its markets overseas and how the United Kingdommay
capitalise on arising opportunities.This has taken place
mainly between government and other stakeholders
and provides useful perspectives on how investment,
manufacturing, technologies and healthcare path-
ways can be deployed to encourage the commercial
translation of CGTs.This provides a valuable context
for examining hypothetical DCM scenarios.
A number of key points recommended in the recent
AdvancedTherapies Manufacturing Action Plan from
the UK Medicines Manufacturing Industry Partner-
ship [15] resonate strongly with DCM. Key
recommendations from the report include a compre-
hensive strategy to secure inward investment, generation
and retention of both manufacturing capability and
a talented workforce within the United Kingdom and
finally using novel social and regulatory approaches
to help grow businesses within the United Kingdom.
With the addition of the Cell and Gene Therapy
CatapultManufacturing Facility to the UK infrastruc-
ture and the assignment of funding to three new
AdvancedTherapyTreatment Centres (see below), the
874 R. P. Harrison et al.
Figure 1. An overview of potential operational paradigms for DCM compared with centralised manufacturing.The CGT product life cycle
can be broken down into multiple process modules, which are then assigned to a geographical region. In a centralised model, these are
primarily carried out at the centralised facility, whereas at a decentralised facility, these steps are distributed throughout the geographical
network.The DCM suite may be located within the clinical centre or elsewhere but will need to retain quality control and quality assur-
ance (QC)/(QA) abilities to perform testing on and between processes (e.g., line clearance).
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United Kingdom as a whole will possess substantial
manufacturing capacity for CGTs.The opening of the
ThermoFisherCryoHub to support logistics anddelivery
of these therapies [16] will enhance the cryogenic supply
chain in a centralised manufacturing model. Despite
this, certainCGTproductswould still benefit frombeing
manufactured in or near the clinical end user.
Support for this DCM approach is in part
recognised by the report that recommends the estab-
lishment of what has become known as ‘Advanced
TherapyTreatment Centres’. £30 million of Central
Government funding has been allocated to establish
three of these [15].These centres are specifically de-
signed to facilitate the creation of viable CGT business
models and support commercial manufacture and for-
mulation in a hospital setting. Part of the mandate of
the funded centres is to garner operational learning
that will facilitate manufacture closer to the pa-
tients.This investment will act as a catalyst for adding
resilience to the provision of CGT treatments and will
add significant value to the UK capability in near-
patient manufacturing.
Regional implications of the shift to high-value
manufacturing
Since the mid-1960s the United Kingdom has lost
more than 6 million manufacturing jobs. In the face
of cost-competition from low-wage economies such
as China, manufacturing in the United Kingdom must
compete by emphasising specialised high-value niches
where it is able to compete internationally [17].
Across the United Kingdom, the number of manu-
facturing jobs has decreased substantially, but The
Midlands and North have been hardest hit, primar-
ily because they contained a larger per capita percentage
share of manufacturing industries than the South. Ad-
ditionally, these Southern locations were often more
able to retain presence in delivery of specialist ser-
vices or research and development during downsizing
operations and thus escaped much of the impact of
the downsizing experienced elsewhere [18].The dif-
ferences between the regions must be considered in
relation to a series of factors, however.These include,
on the one hand, the abundance of access to support
services and related industry in the South-East and,
on the other hand, the accompanying expense of op-
eration that is driven by market forces in relation to
those advantages [17].
As the trend toward high-value manufacturing con-
tinues, it changes the composition of the workforce [19].
Factories of the mid-20th century consisted of a mul-
titude of workers undertaking a limited range of tasks.
The factories for high-value manufacturing in the future
will largely consist of automated tasks and the role of
the worker will be mainly that of oversight, mainte-
nance or programming.This is a relatively high-skill task
and will require a skilled work-force commanding a
Figure 2. Candidate manufacturing platforms for adherent (monolayer) and suspension (stirred tank reactor) culture of CGTs.
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relatively strong salary.This change would benefit many
regions of the United Kingdom provided that the re-
gional population has access to the requisite training.
The investment in the Cell and Gene Therapy
Manufacturing Facility is an example of the
‘agglomeration economy’, which is based on the prin-
ciple that companies operate more effectively if they
are near other similar companies and can benefit from
shared supply, demand and skilled labour [20]. A
variant on this theme is centred on the idea that in-
novative manufacturing functions best when located
next to universities and research environments.Anyone
doubting this apparent effect in the biotechnology
sector only needs to examine Boston and Cam-
bridge in the United States to witness how the
concentration of biotechnology-focussed companies
has created an inflection point for the industry like
no other globally. DCM offers an interesting alterna-
tive paradigm whereby a business can benefit from
centralisation of its core facilities while situating an-
cillary DCM centres in geographically diverse regions
close to the end point-of-care. The drive to decen-
tralise could come from tax concessions or other
regional government incentives yet would have the ad-
ditional benefit of providing meaningful employment
to other disparate regions.
Materials and methods
Overview
Establishing a DCM network poses numerous chal-
lenges, yet predicates already exist in allied healthcare
sectors that could be used to derive a theoretical manu-
facturing process and supply chain model [13]. Despite
the similarities of these sectors to a potential manu-
facturing scenario, there are key differences that would
influence a CGT manufacturing network [13].These
existing paradigms and guidelines were used to inform
the creation of a model and case study examining the
manufacture of allogeneic cell therapies in a UK re-
gional setting.
Any emerging businessmodel would have to adhere
to current good manufacturing practice (GMP) stan-
dards and assure control across a network of facilities.
The granular details on how this could be accom-
plished in the case of DCM are currently unknown,
and are likely to remain uncertain for the short term,
while the necessary engineering research takes place
to allow quality control (QC) and comparability to be
enforced across sites using technological solutions [21].
The situation may be likened to an equation with too
many unknown variables and this gives the opportu-
nity to consider what the economic and operational
impact would be for some of the possible options.We
offer this article to inform the growing industrial and
academic dialogue aboutwhich operationalmodels hold
the greatest potential for healthcare, employment and
economic impact in regional development.We believe
that there is currently an opportunity for stakeholders
to shape policy as the eventual regulatory environ-
ment is likely to be driven by a growing confidence
arising from the combined opinions of researchers,
equipmentmanufacturers, product manufacturers and
regulators working together to scope out suitablemodels
and to deliver sustainable clinical success.
A range of business pressures were examined, in-
cluding the role of the geographical region in shaping
facility rollout, economic decisions affecting QC strat-
egies, in-process losses (of the active pharmaceutical
ingredient, in this case, the cell, and the final drug
product), staffing across the network and finally the
directionality and frequency of shipping.
Model design
A process economics modelling tool was developed
to examine a network of DCM facilities organised
around a supporting hub facility. This model con-
sists of a graphical user interface (GUI) developed using
the Microsoft Excel platform with integrated Visual
Basic for Applications (VBA; Microsoft Corpora-
tion) script.This model uses an established database
of parameters combined with user-specified vari-
ables to predict technical manufacturing outputs as
well as financial performance. Individual facilities were
examined as points in a manufacturing network to build
a picture of a networked manufacturing strategy.
Required manufacturing capacity was calculated
based on the number of patient doses required across
all geographical regions served by a DCM ‘node’ per
year.The network comprised ‘central hubs’ from which
starting materials and optionally services are sup-
plied at the level required for regional manufacturing
sub-facilities or ‘nodes’ that manufacture appropri-
ately sized batches for regional supply to networks of
regional users.The central hub facility was specified
to produce seed doses as an intermediate product ‘kit’
for onward expansion at decentralised node facili-
ties, assuming 20% excess doses each year. Biological
characterisation of cell sources was used to establish
lot size yield projections and to establish the re-
source consumption and equipment requirement of
the upstream and downstream processes. Baseline
values for facility size, office space and staffing re-
quirements were established in the model.
Cost of goods (COG) of a particular process con-
figuration consists of annual direct costs (materials,
labour staffing and QC) and indirect costs (facility and
equipment costs and loan servicing) as described in
Figure 3. Facility and equipment were amortised over
10 years as suggested by the Worldwide Capital and
Fixed Assets Guide [22]. Loan agreements were
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assumed at 10 years at 5% interest. An investment dis-
count factor was not applied and could be factored in
later as required. Staffing costs are calculated per sal-
aried full-time individual. Administrative costs are
captured solely in the employment of administrative staff
and associated training, not through any other costs or
multipliers. Research and development and sales costs
are not captured by this model. A further breakdown
of costs is located in the Supplementary Material.The
breakdown of costs describes the staffing levels at each
facility with the staff expected to perform all ancillary
services such as health and safety, regulatory support
and environmental monitoring. In certain cases, addi-
tional costs could be considered necessary.
Model sources
Tables of all process and cost assumptions used within
the model are detailed in the Supplementary Mate-
rial. Medical technology company data were provided
by the Association of British Healthcare Industries
(ABHI) and the location data of cleanrooms from the
Cell and GeneTherapy Catapult Annual Review 2016
[23].
Salary bands were based upon the National Health
Service Pay Scales.These were adjusted to reflect re-
gional variations using the Annual Survey of Hours
and Earnings (ASHE)—Office for National Statis-
tics.These were then combined to create salary banding
with regional disparities.
Estimated population densities for UK regions were
identified using PopulationExplorer [24] (Kimetrica)
and Landscan [25].These tools were used to identi-
fy high-value target areas for placement of the ‘hub’
or ‘node’ sites and are presented in Supplementary
Figure S1.
Business Ratable Values were obtained from the
Valuation Office Agency 2005 and 2010 Local Rating
Lists and were adjusted using the relative national
change to account for the 2017 changes [26]. A mul-
tiplier was extracted to apply to each of the UK regions.
Business rental values were obtained from Col-
liers International National Office Rents Map 2016
[27]. Service charges were obtained from Simon Korn
Commercial Property Consultants for London and ex-
trapolated for other regions [28]. Values were for a
‘grade A’ new-build unit in a prime location.
Case study
DCM is a significant departure from the traditional
centralised manufacturing explored in most process
economics and COG case studies.The case study pre-
sented here is informed by previous exploratory
research detailing the potential operational scenarios
for businesses engaging in DCM [29]. Business rates,
Figure 3. COG calculation methodology for the DCM network. In brief, materials, labour (including training), QC (as a subdivision of
labour and materials), indirect costs, facility costs and equipment costs were calculated for the central and decentralised node facilities.
These were then combined to calculate the overall total COG for the whole DCM network. Labour costs arise solely from employment of
full-time staff as described in the Supplementary Material; there are no part-time or indirect labour costs accounted for. Further infor-
mation can be found in the Supplementary Material.
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regional wage disparities, rental rates, service charges
and population metrics used are described in theModel
Sources section.
The manufacturing process describes a theoreti-
cal allogenic or partially patient-matched mesenchymal
stromal cell (MSC) therapeutic (Figure 4).The ther-
apeutic is manufactured in a DCM ‘node’ supported
by the centralised ‘hub’ facility.The benefit of choos-
ing a universal-donor therapeutic model rather than
patient-specific, is that one lot to one patient begins
the study with the simpler case before turning in due
course to the complexity of autologous supply with
significantly increased costs [30,31].These costs are
magnified further with DCM due to QC, transpor-
tation and logistics [21].
Scalable cell expansion technologies have been iden-
tified as a key factor in driving down the manufacturing
costs for CGTs [21,32]. For DCM, these scalable plat-
forms are likely to be smaller scale and modular with
isolated product streams to separate out the batches
and to allow efficient line-clearance procedures [33].
We have previously examined putative manufactur-
ing platforms for these products [6] and for the current
research we have costed a modular, scaled-out
microcarrier-based expansion platform adapted from
published works [34].This hypothetical manufactur-
ing platform uses small-volume (250 mL) self-
contained process modules that are controlled in
batches of 10–30 by a central control system.This plat-
form is ideal for the 100,000 cells/kg body weight
(75,000,000 cells total per patient) dose described in
this manufacturing case study.This case study assumes
500 doses manufactured at each location per year
(5000 total/annum).There is no accounting for dose
Figure 4. Process flow diagram outlining key features of the hypothetical MSC case study. In brief, the incoming allogeneic cell source is
expanded in the central facility to create the cryopreserved master bank. Upon receiving approval for the intervention, the banked product
can be further expanded to produce the final fresh formulated product.This is then transported the short distance to the clinic where it is
prepared for administration by the clinician.
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ramp-up or idle capacity accounted for in this model.
Because the decentralised model looks to minimise idle
capacity, potential cost reductions could be realised
through efficient use of the high-cost fixed assets [35],
although this must be balanced with the increasing
challenge, and potentially significant cost of coordi-
nating production and supply from distant parts of the
network. A process flow diagram outlining the hypo-
thetical manufacturing strategy described herein is
presented in Figure 1.
DCM splits manufacturing capacity across geo-
graphical regions and, in doing so, imposes constraints
on the structure of a company. Several factors must
be considered when identifying which geographical
regions will not only have the demand, but also the
supply of strategic assets, transportation routes, re-
sources or people. In brief, these consist of demand
(population within serviceable areas of the decentral-
ised node), supply of strategic assets (international
transit hubs) and workforce (supply of highly trained
individuals within the medical technology sector).These
factors were used alongside the Science and Innova-
tion Audits [36] to identify putative regional
manufacturing centres across the United Kingdom
(Supplementary Figure S1).The selected sites provide
catchment for 60% of the United Kingdom with pop-
ulation outside a direct catchment area still being
represented locally by a node within their extended
area.
Results and discussion
Regional variations and pressures
Across a DCM network, the nodes and a hub are sit-
uated within a variety of geographic regions. These
regions have different environmental factors, each of
which contributes to differing cost and social pres-
sures on the business [37]. Some of these trends are
clear; for example, land and wages are dramatically
higher in many Southern regions when compared with
their Northern counterparts. Other trends are less
obvious, such as the underlying benefits businesses
receive when located in regions densely populated with
similar businesses.
Each geographic region is likely to have differing
rents, business rates, service costs and staff salaries.
These factors combined have an effect on the overall
cost of situating a business presence within that region.
The variance between these costs across regions of the
United Kingdom is shown in Figure 5 for the central
hub facility (A) and the decentralised node facilities
(B). Understandably, London is significantly more
costly than the other regions, although, perhaps sur-
prisingly, other regions show relatively low variation.
Regional wage variation is the largest source of cost
differential and it is thus unsurprising that the differ-
ence between the costliest and least costly regions is
greatest for the central facility compared with the prov-
inces where staff costs are a greater proportion of total
ongoing costs. It is important to note that DCM relies
upon local skills being available. These data do not
incorporate any expenditure that may have to be al-
located to either entice talent to regions that lack the
sufficient skills pool, compete for existing skilled in-
dividuals in a highly competitive environment or retrain
individuals once the facility has been established.
The role of London in contributing to the effi-
ciency of an operation can be substantial. The
abundance of transport links for air, ground and sea
freight, the internationally renowned specialist hos-
pitals and the associated abundance of skilled labour
make it a destination of choice for high-value, low-
volume, high-margin personalised therapies. However,
the balance of costs may not work so well for lower-
margin, high-volume products. For a DCM paradigm,
each facility is part of a wider network and thus should
not be considered in isolation. Figure 5C presents these
facilities as an integrated network with the central fa-
cility moving between each respective region.When
examining this extended decentralised network, it
becomes clear that, if the central hub facility is situ-
ated outside of London, the business can reap
significant savings. Because there is still a node present
within London, this saving is made while still provid-
ing the same clinical provision to the region. When
examined on a price per dose level the greatest savings
can be gained by not situating within London. COGs
within London are approximately £2000 per dose
whereas the regions range from £1795 (Notting-
ham) to £1850 (Edinburgh).This obviates the easiest
savings that are gained by situating outside of the
London area with smaller incremental savings to be
made between competing regions.
Although at first glance these savings may seem
minor, particularly when examined as a cost per dose,
it is illustrative to examine what the savings thus reaped
could be re-invested into. If the primary hub is placed
outside London, between 25 (Edinburgh) and 41 (Not-
tingham) extra operators could be employed to
manufacture product (Figure 6A; defined as junior op-
erators, excluding training costs). Alternatively, in a
DCM network, the dominance of automated manu-
facturing platforms may make investment in more
manufacturing process modules attractive (Figure 6B;
defined as 1/24th of an additional bioreactor plat-
form). In this scenario, between 25 (Edinburgh) and
34 (Nottingham) additional process modules could
be integrated across the wider manufacturing network.
The COG savings must be considered as part of
a wider business case considering clinical indication,
patient volume and reimbursement price.With a the-
oretical reimbursement threshold for this product of
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£50,000, the margin in London would be 96% versus
96.3% in Edinburgh.This presents a large COG saving,
yet this may present a poor business case with little
difference between the two locations.This highlights
the importance of both considering COG as part of
a wider business case, but also the likely necessity of
additional regional investment factors to drive DCM.
It is important to remember that cost alone is not
the only determinant of where to situate compo-
nents of a decentralised network. London has
significant financial costs associated with it that drive
up the cost of doing business. However, London ben-
efits from a high density of technical skill, but also easy
access to extrinsic aspects of the business. Examples
include easy access to some of the world-leading clin-
ical centres and universities, financial businesses,
venture funds and regulators. These assets concen-
trate money, staff, expertise and key management skills
required for businesses to thrive and reduce the over-
head cost of simply ‘doing business’ in this sector [38].
Although this is a self-reinforcing attraction for busi-
nesses to situate their primary premises within London,
efficient transportation networks have minimised travel
times to the point where regions immediately north
of London are benefitting from the spill-over of the
high concentration of these extrinsic factors. Indeed,
the Cell and GeneTherapy Catapult Manufacturing
Centre is a case in point, retaining a presence within
the Capital yet situating a manufacturing centre further
north (yet still within the ‘Golden Triangle’).
The United Kingdom has a long history of policy-
making geared toward regional development dating
back to the 1930s [17]. High-value manufacturing un-
doubtedly has a strong part to play in rebalancing the
economy and contributing to economic growth of the
United Kingdom [39]. However, both conventional
wisdom and global trends highlight the importance
of specialist hubs such as Boston and Cambridge in
the United States, which are able to readily attract
companies from the surrounding area. Recent
Figure 5. Economic pressures affecting business sites and regional placement of a manufacturing network. Location of a central facility in
a geographical context can be seen to have a profound effect on running costs per annum due to a combination of increased property
values, service costs and business rates (A). Similar trends are present for smaller DCM hubs (B) with London being the highest cost
location.When these values are used as part of a larger decentralised network (C), it becomes clear that if the larger bulk of the business
is situated outside London, significant savings can be made with the same provisioning of end-point clinical products. In a price per dose
cost, it is obvious that although there is value to be had situating in cheaper regions, the main savings are had by not situating in London
(D). Costs comprise yearly office space costs, yearly facility costs (excluding materials), business rates and service charges as well as staff
costs. Average costs are signified by the red line. (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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high-profile examples of this have included Blue Rock
Therapeutics which moved from Toronto to Boston
to tap into not only the technical expertise, but also
the wider entrepreneurial environment.This effect is
reflected to a lesser extent in the Cambridge, Oxford
and London ‘GoldenTriangle’ in the United Kingdom.
This area similarly is able to attract business and inward
investment. DCM with a ‘hub’ in Cambridge (United
Kingdom) and ‘nodes’ across the United Kingdom
could both benefit from this ‘agglomeration economy’
and offer manufacturing employment across the UK
regions while providing a viable trade-off between
Figure 6. Visualising the potential savings realised through smart geographical business placement. If the main manufacturing hub is placed
outside London, between 25 and 41 extra operators could be employed across the decentralised network (A). Alternatively, in a chiefly
automated production system, it could be possible to expand production by 24–35 extra reactor vessel modules, which each allow another
production lot to be run in parallel (B). Assumptions: staff salary band £27.3 k/annum, reactor vessel module cost 32.7 k. This is an il-
lustrative example and expansion would be driven by patient projections.
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economic prudence and sound business manage-
ment. Consequently, for the subsequent model outputs,
the decentralised network will assume that Cam-
bridge is the decentralised ‘hub’.
Decentralisation of QC
As manufacturing strategy progressed from pre-
industrial bespoke manufacture towards industrialised
batch production, the demand for product variation
decreased. Since the 1990s, the desire for flexible
manufacturing, able to respond continually to chang-
ing markets, has increased [40]. DCM represents a
return to small-scale manufacture and much of the
research is geared toward creating the manufactur-
ing platforms able to perform the process.Yet, one of
the key uncertainties remaining is how to maintain
quality control from a distance [41].
Current approaches to allogeneic CGT manufac-
ture require a panel of QC tests that require not only
specialist physical resources, but also appropriate sig-
nificant technical expertise [42], which may not be
locally available at each site.This represents a signif-
icant investment in both resources and staff at each
location, to provide the level of QC characterisation
that is suggested to be necessary [42].Thus, there is
significant advantage for DCM if it were possible to
centralise QC resources.The obvious example would
be locating the QC facilities at the ‘hub’ with decen-
tralised ‘nodes’ providing material or data collected
locally.
For this case study, three options for QC were ex-
amined: fully centralised, fully decentralised and
partially centralised.The QC profile was modelled on
a real-world assay panel and sub-divided into a basic
panel of current practice (cost approximately £6,000
per batch) and an extended panel including emerg-
ing -omics and genetic testing (cost approximately
£37,500).These are further described in the Supple-
mentary Material. The total COG over a year is
presented for the basic panel (Figure 7A) and ex-
tended panel (Figure 7B).The per dose cost of these
three QC strategies are presented (Figure 7C and 7D).
These demonstrate that significant cost savings can
be realised through centralisation of QC.Although this
is unsurprising, it is valuable to realise that equiva-
lent savings can be realised through only partial
centralisation of QC.
When further examined, the total contribution of
QC from each aspect of the decentralised network can
Figure 7. Economic considerations of differing QC strategies for DCM networks.Two QC assay panels based on current commercial MSC
product testing were examined.These were costed at approximately £6,000 and ~£37,500, respectively. Three QC strategies were exam-
ined: “fully decentralised” (staff at each sub-facility), “partially centralised” (some staff at each decentralised facility supported by centralised
staff) and “centralised QC” (all QC is performed centrally). The cost of QC as a total COG is presented as a treemap highlighting the
constituent values for the £6,000 (A) and £37,500 (B) QC panels. The total dose reimbursement cost for products produced across the
decentralised network is presented for the two £6,000 (C) and £37,500 (D) QC panels highlighting the variation in production costs across
regions. Centralised QC location is the Cambridge hub facility.
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be visualised. As QC is increasingly centralised, more
of the QC burden falls on the centralised hub. Sur-
prisingly, however, these data suggest a hybrid QC
strategy may not only be easier to implement, but may
also allow for equivalent cost savings when com-
pared with complete decentralisation of QC. These
savings are hypothesized to be enabled by using tech-
nical staff to run the simpler assay panel locally while
the complex panel is outsourced to the central facil-
ity. Thus, a relatively cost-efficacious labour force
provides local assay expertise while the challenging as-
sessments that require expensive capital expenditure
and costlier labour are able to benefit from the cen-
tralisation cost-reduction methods. This practice of
releasing ‘at risk’ [1] is an accepted practice in
radiopharmaceuticals and oncology and this effort to
partially decentralise would allow the local assay panel
to build up enough confidence to release the product
on the assumption that the full assay panel will be com-
pleted to validate the release criteria.
Although these data provide key insight into the
potential high-level costings of these three approaches,
it is important to keep in mind that it is not cur-
rently clear whether this approach would be feasible
from a technical or regulatory compliance perspec-
tive. With a typical time window for in process QC
testing of samples of 2–3 hours with current testing
procedures, it would be challenging to transport
samples and receive meaningful insights. Similarly, there
is a very real possibility that for some tests it may be
more cost effective to outsource to a third party.
The impact of product loss from the manufacturing
value chain
Current culture platforms are far from perfect and
deficiencies in manufacturing result in lower cell
yields per cycle and consequently a higher product
price [14,43]. Similarly, CGT products are exqui-
sitely sensitive to uncontrolled variations in the
distribution chain.Thus, measures must be taken to
provide robust environmental control not only during
the manufacturing or culture period, but also during
any logistical or shipping steps. The former has re-
ceived substantially more attention and investment
and potential purpose-built culture environments are
beginning to be available for CGT manufacture.
Historically the issue of the CGT supply chain has
been relatively under-funded [44] and only recently
have substantial product advances and investment
decisions beyond mandatory characterisation oc-
curred [45]. These include dedicated facilities such
as the Fisher CryoHub for storage, distribution and
logistics, services such as Cryogatt RFID andTrakCel
for audit and chain of custody and products such as
the Asymptote Thawer for automated reconstitu-
tion. Despite these advances, product loss within the
manufacturing value chain remains a substantial threat
to efficient and cost-effective production worthy of
examination.
When modelling the cell manufacturing process,
it was observed that small to moderate cell losses of
up to 35% were tolerated in the manufacturing process
itself for the three MSC cell types (Figure 8A). Losses
up to 35% did not increase the final dose price sig-
nificantly, but at >35% in-process cell loss, doses
quickly increased in cost and this effect was magni-
fied for cell types with poorer growth kinetics. This
relative cost-susceptibility of low expansion-potential
cells is due to the fewer doses achieved per lot with
similar resource expenditure on consumables. Manu-
facturing research and appropriate culture equipment
able to administer fresh media or other consumables
such as growth factors only when required rather than
to a fixed menu would reduce this cost differential,
but these hypothetical systems are yet to be imple-
mented. Loss of a fresh (not frozen) product post-
manufacture was examined (Figure 8B) and
demonstrated an increase in cost per dose across all
cell types.
One of the suggested drivers to decentralise [29]
is to minimise the end product logistical burden and
associated product loss. Product loss was plotted against
increasing numbers of technical operator-level staff at
the decentralised node facility (Figure 8C).This was
plotted against increasing post-manufacturing product
loss. As more staff are employed at the central facil-
ity, the total COG and subsequent dose cost increases.
Interestingly however, dose loss in transit is a less im-
portant influence on COGs and, assuming in-transit
losses can be kept at 50% or below, reduction of staff
at the DCM facilities becomes a much more influ-
ential cost-reduction measure. Also of note is the
relative absence of cost difference between the
‘minimal’, ‘normal’ and ‘high’ staffing levels at the
central facility.This suggests that outsourcing tasks such
as QC to the central facility as a means of reducing
the staffing footprint at the decentralised facilities would
be a commercially viable option.
The impact of product loss during distribution
Even with DCM, it is necessary to perform a certain
level of shipping for each product manufacturing cycle,
albeit over small distances to regional clinical centres.
Depending on the exact business model and QC strat-
egy, the decentralised network may comprise of
anything from a unidirectional hub-to-node, low-
cost cryogenic shipping strategy to a multi-directional
approach with several shipping cycles per dose pro-
duced.The causes of multi-directionality in the logistics
chain are highlighted in Figure 9.
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CGTs are a ‘living drug’ and sensitive to environ-
mental conditions, such as temperature and humidity,
all of which can have an impact on the viability of the
drug and its effectiveness. Controlling these condi-
tions are arguably more challenging with ‘fresh’ less
stable, non-cryogenically preserved cell products due
to the narrow physical and time parameters required
for success.These products essentially remain in culture
during transport and require active management of
the product. Specialist packaging containers and en-
vironmental management products exist that aid in
fresh shipping but if the product has a time-sensitive
shelf-life then costs can quickly mount up for dedi-
cated transportation over anything other than short
distances.The cryopreservation of products requires
expensive equipment within the distribution chain, yet
increases the maximum transit duration dramatical-
ly, which allows pooling of deliveries and thus a
reduction in freight costs (Personal Communica-
tion, Steve Langron, Lime Associates). In this case
study a ‘fresh’ therapeutic formulation is examined to
evaluate the impact of potential cost reduction methods.
Both per-dose costs and strategies to reduce the cost
by bundling doses into multi-product shipments are
Figure 8. The effect of cell and product loss during the manufacturing value chain. Small to moderate cell losses (up to 35%) in process
do not profoundly shift the cost per dose (A). Product loss post-manufacturing was examined (B). Increasing in-transit dose loss from a
centralised facility to receiving clinical facilities was plotted against the cost of employing increasing numbers of staff at decentralised manu-
facturing sites across the network (C). Low staffing in the central facility consists of 17 staff members, medium is 22 members and high
is 32 members.The lowest decentralised staffing consists of one administrator, one technician and one of each junior, standard and senior
operator. The highest decentralised staffing consists of one administrator, one technician, three senior technicians, four junior, two stan-
dard and three senior operators as well as two senior scientists. Additional support staff may be seconded for tasks such as cleaning and
monitoring at additional cost from the adjacent clinical facility.
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presented (Figure 10A). By packaging doses into ship-
ments, the increased cost burden arising from increased
travel directionality of materials flow between central
and decentralised node facilities can be offset.The re-
gional cost per dose is largely uniform across regions,
reflecting the similar cost between manufacturing sites
(Figure 10B).
The relationship between individual product loss
from a shipment and whole shipment loss (e.g. due
to poor management of transit) was investigated
(Figure 10C). Bundling of doses into shipments helps
to reduce the chances of doses falling out of specifi-
cation. On the other hand, dose bundling increases
the cost sensitivity if a whole shipment falls out of spec-
ification.These data suggest that if 10% of shipments
are routinely lost or late, bundling four rather than eight
would be financially prudent. It is important to note
that the number of doses able to be pooled into one
container will be driven not only by costs, but also by
patient volume and ability to receive samples at the
treatment site.All of these data assume adequate transit
trials have been completed to validate the shipping con-
ditions for the product. Similarly, many of these costs
may present as lower values in the form of excess in-
surance payments because it is likely a manufacturer
will insure against this risk.
Logistics, QC and flexible decentralisation
Undoubtedly enacting a full DCM network is a chal-
lenging prospect due to the substantial shift it
represents from traditional manufacturing practices.
Both efficient logistics and QC are critical aspects in
evaluating the feasibility of the potential network but
taken together they introduce an important ques-
tion: How far should the value chain decentralise to
gain the purported benefits while avoiding the chal-
lenges? This hybrid decentralisation approach is
informed by the relationship between QC COGs, lo-
gistical COGs and necessity for localised responsive
manufacturing. A sample partially decentralised QC
process is highlighted in Figure 11.
One of the key questions remaining is that of com-
parability between sites and ensuring that the material
that left one site is equivalent to that entering the next.
This will require comparability studies, but past expe-
rience would suggest that this logistical burden is
manageable using both cryogenic and refrigerated
Figure 9. Levels of directionality and complexity in the logistical chain of a DCM network highlighting the potential movements between
facilities. Not all paths may be present in all DCM scenarios. Materials can flow in multiple directions from clinic to node to central fa-
cility depending on the manufacturing strategy of the product. It is important to note each direction of travel may occur more than once,
several batches of QC may be outsourced, or multiple treatment doses shipped to the clinic in set intervals.
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storage shipping in tandem (Dendreon) [46,47] or re-
frigerated storage alone (Carticel and ChondroCelect)
[46]. Similarly, these data presented here suggest lo-
gistical COGs are not a large component of total COGs
and both of these factors are likely to improve with the
increased investments recently in logistics and supply
chain management. This leaves the requirement to
manufacture locally and the feasibility and cost of ad-
ministeringQCas the key trade-offs for opting forDCM.
This research has suggested a hybrid QC strategy
is practical from a COG perspective. The question
remains, will the regulator have an appetite for this
flexible hybrid QC strategy?We would argue that the
necessity for this in biological products is already ap-
preciated [48], yet the paradigm already exists in the
practice of releasing at risk for oncology products.These
are allowed to be released to the patient after fulfill-
ing aminimal release panel on the proviso the full follow-
up panel is completed post-use. Based on these data
and the wider experience of related fields,DCMusing
a hybrid QC approach may not only represent a cost-
efficacious approach, but also a potentially feasible one.
Figure 10. The effect of product loss through extraneous issues, such as loss and damage in the distribution chain versus doses falling out
of specification due to in-transit delays. As the frequency of product or dose transit goes up, the cost per dose increases, but this can be
offset by packaging doses into shipments (A). The cost per dose (without shipping) is largely uniform across regions (B). As doses are
packaged into shipments (C) the cost impact of failures in the distribution chain are magnified (blue line). However, an efficient transport
chain that minimises loss of product during distribution can help overcome increasing costs due to individual dose loss (e.g., falling out of
specification mid-transit due to unexpected delays; red line). (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
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Conclusions and forward-looking statement
DCM is an attractive proposition for personalised med-
icine. In this period of growing concern over efficient
use of energy, avoidance of waste and the environ-
mental impact [49] of long-distance, temperature-
controlled shipping [50] there is an extra driver to
manufacture close to the point of use.
A hub-and-node model of operation can be at-
tractive because it is a vehicle to drive regional
development and job creation and can be appealing
to patients who wish to avoid travelling long dis-
tances for treatment.The specialist treatment centres
put forward by Porter et al. [51] can be regarded as
the forerunner of this approach to the manufacture
and application of cell-based therapies if it were to be
integrated with a small, specialised manufacturing unit
as the ‘node’.
In the United Kingdom there is increasing oppor-
tunity and appetite to explore this route to market
access using private and public investment sources [15].
It is important to right-size the facilities to make them
sustainable.We have begun to examine the cost im-
plications of some of the underlying choices because
this is the economic foundation of the operational
design. These economic insights into COG must tie
into the clinical indication, patient volume and
Figure 11. Illustrative diagram of a QC panel for a mesenchymal stromal cell (MSC) therapy. Simpler tests requiring fewer specialised
personnel and items of equipment are located at the node of clinical facilities, whereas the more complex, longer duration and costly assays
are outsourced or returned for analysis at the central facility. In this scenario, the decentralised facility would require QC laboratories,
operated under appropriate GMP requirements. Additionally, many of the tests are unable to give results in real-time and thus product
may have to be released at risk.
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reimbursement price to formulate sound business cases
that are driven by an analysis of all these constituent
parts, not just the underlying COG.
The next stages in this process will be to look at
the interface with the clinical pharmacy services and
procurement to ensure smooth hand-offs in the chain
of custody, to identify the appropriate QC arrange-
ments with supporting technology and to find the point
in the mechanisation-automation spectrum where there
is a sweet spot between the cost of technology de-
ployment and the appropriate confidence in process
comparability site-to-site.
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